Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

Additional chromosomal abnormalities (ACAs) in Philadelphia-positive cells have been reported in ∼ 5% of patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP). Few studies addressing the prognostic significance of baseline ACAs in patients treated with imatinib have been published previously. The European LeukemiaNet recommendations suggest that the presence of ACAs at diagnosis is a "warning" for patients in early CP, but there is not much information about their outcome after therapy with tyrosine kinase inhibitors. To investigate the role of ACAs in early CP CML patients treated with imatinib mesylate, we performed an analysis in a large series of 559 patients enrolled in 3 prospective trials of the Gruppo Italiano Malattie Ematologiche dell'Adulto Working Party on CML: 378 patients were evaluable and ACAs occurred in 21 patients (5.6%). The overall cytogenetic and molecular response rates were significantly lower and the time to response was significantly longer in patients with ACAs. The long-term outcome of patients with ACAs was inferior, but the differences were not significant. The prognostic significance of each specific cytogenetic abnormality was not assessable. Therefore, we confirm that ACAs constitute an adverse prognostic factor in CML patients treated with imatinib as frontline therapy.

[1]  N. Munshi,et al.  MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. , 2013, Blood.

[2]  Martin C. Müller,et al.  Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. , 2011, Blood.

[3]  M. Baccarani,et al.  Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. , 2011, Blood.

[4]  J. Radich,et al.  NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  E. Lippert,et al.  Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy , 2010, Haematologica.

[6]  M. Baccarani,et al.  Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. , 2010, Cancer genetics and cytogenetics.

[7]  M. Baccarani,et al.  Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Z. Estrov,et al.  Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy , 2010, Cancer.

[9]  J. Radich,et al.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Carcassi,et al.  Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. , 2009, Blood.

[11]  Jorge Cortes,et al.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia. , 2009, Blood.

[12]  K. Rezvani,et al.  European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. , 2008, Blood.

[13]  Martin C. Müller,et al.  Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. , 2008, Blood.

[14]  Jaspal Kaeda,et al.  Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Baccarani,et al.  Monitoring treatment of chronic myeloid leukemia , 2008, Haematologica.

[16]  N. Archidiacono,et al.  "Home-brew" FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia. , 2007, Cancer genetics and cytogenetics.

[17]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[18]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[19]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[20]  M. Baccarani,et al.  Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients , 2006, Clinical Cancer Research.

[21]  H. Kantarjian,et al.  Staging of chronic myeloid leukemia in the imatinib era , 2006, Cancer.

[22]  Susan O'Brien,et al.  Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate , 2005, Clinical Cancer Research.

[23]  Jorge Cortes,et al.  Clonal evolution in chronic myelogenous leukemia. , 2004, Hematology/oncology clinics of North America.

[24]  H. Kantarjian,et al.  Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome , 2004, British journal of haematology.

[25]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[26]  J. Gabert,et al.  Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects , 2003, Leukemia.

[27]  H. Kantarjian,et al.  Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. , 2003, Blood.

[28]  M. Deininger.  Cytogenetic studies in patients on imatinib. , 2003, Seminars in hematology.

[29]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[30]  W. Hiddemann,et al.  Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate , 2003, Leukemia.

[31]  B. Druker,et al.  The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. , 2002, Blood.

[32]  B. Johansson,et al.  Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia , 2002, Acta Haematologica.

[33]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[34]  E. Macintyre,et al.  Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.

[35]  H. Heimpel,et al.  Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. , 1988, Blood.

[36]  E. Gehan,et al.  Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. , 1985, Blood.

[37]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[38]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[39]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[40]  Martin C. Müller,et al.  Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia : an analysis from the International Randomized Study of Interferon and STI 571 ( IRIS ) * , 2010 .

[41]  L. Shaffer,et al.  ISCN 2009 - An International System for Human Cytogenetic Nomenclature , 2009 .

[42]  G. Saglio,et al.  Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories , 2008, Leukemia.

[43]  H. Kantarjian,et al.  Introduction: chronic myelogenous leukemia (CML). , 2007, Seminars in hematology.

[44]  D. Marin,et al.  Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. , 2003, Haematologica.

[45]  F. Mitelman.  The cytogenetic scenario of chronic myeloid leukemia. , 1993, Leukemia & lymphoma.

[46]  A. Hagenbeek,et al.  Minimal Residual Disease in Acute Leukemia , 1984, Developments in Oncology.